Spikevax (Moderna mRNA-1273 COVID-19 vaccine) for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. control
vs. placebo
vs. uncontrolled study

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 0

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

teenCOVE (P203) (Adolescents 12-17Y), 2021 NCT04649151

Spikevax (Moderna mRNA-1273 COVID-19 vaccine) (n=2489) vs. placebo (n=1243)

randomized controlled trial

Studied treatment

Two vaccinations of mRNA-1273 given 28 days apart
Each injection containing 100 μg, for a total dose of 200 μg, 28 days apart.

Control treatment

Placebo
Two doses 28 days apart.

Patients

COVID-19 prophylaxis (children)

Method

Double-blind.

26 sites in the United States.

Remark

Phase 2-3.

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open